Your browser is no longer supported. Please, upgrade your browser.
Settings
RAPT [NASD]
RAPT Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.25 Insider Own1.10% Shs Outstand24.45M Perf Week-4.86%
Market Cap499.74M Forward P/E- EPS next Y-2.71 Insider Trans-89.73% Shs Float23.71M Perf Month-9.20%
Income-53.40M PEG- EPS next Q-0.59 Inst Own87.40% Short Float3.63% Perf Quarter-37.78%
Sales3.70M P/S135.06 EPS this Y-19.00% Inst Trans6.85% Short Ratio1.94 Perf Half Y-12.22%
Book/sh4.50 P/B4.56 EPS next Y-21.00% ROA-42.30% Target Price36.17 Perf Year-57.96%
Cash/sh5.05 P/C4.07 EPS next 5Y- ROE-48.80% 52W Range10.52 - 51.21 Perf YTD4.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-61.45% Beta-
Dividend %- Quick Ratio8.10 Sales past 5Y- Gross Margin- 52W Low87.66% ATR1.26
Employees71 Current Ratio8.10 Sales Q/Q- Oper. Margin- RSI (14)41.01 Volatility5.62% 6.29%
OptionableYes Debt/Eq0.00 EPS Q/Q-36.50% Profit Margin- Rel Volume0.42 Prev Close20.54
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume443.50K Price19.74
Recom2.00 SMA20-4.36% SMA50-7.77% SMA200-20.22% Volume154,147 Change-3.89%
Jun-01-20Initiated H.C. Wainwright Buy $40
May-19-20Initiated Cantor Fitzgerald Overweight $37
Apr-13-20Initiated ROTH Capital Buy $38
Nov-25-19Initiated Wells Fargo Outperform $33
Nov-25-19Initiated UBS Buy $26
Nov-25-19Initiated BMO Capital Markets Outperform $35
Jan-07-21 04:30AM  
Jan-05-21 08:00AM  
Dec-28-20 10:16AM  
Dec-15-20 11:26PM  
Nov-23-20 08:00AM  
01:24AM  
Nov-16-20 08:00AM  
07:30AM  
Nov-15-20 07:30AM  
Nov-13-20 08:00AM  
Nov-11-20 09:43AM  
Oct-14-20 08:00AM  
Sep-27-20 10:25AM  
Sep-03-20 08:32AM  
08:00AM  
Sep-01-20 02:53PM  
Aug-13-20 10:47AM  
Aug-05-20 08:00AM  
Jul-23-20 08:14PM  
Jul-02-20 11:24AM  
Jun-18-20 04:05PM  
Jun-17-20 08:00AM  
Jun-04-20 07:49AM  
May-29-20 08:00AM  
May-26-20 08:00AM  
May-19-20 07:47AM  
May-18-20 07:55AM  
May-17-20 10:38AM  
May-15-20 08:00AM  
May-14-20 08:00AM  
08:00AM  
May-12-20 08:00AM  
Mar-30-20 08:00AM  
Mar-04-20 08:00AM  
Feb-19-20 08:00AM  
Feb-07-20 06:45AM  
Feb-04-20 05:43PM  
Jan-31-20 11:27AM  
Jan-07-20 08:00AM  
Dec-16-19 08:00AM  
Dec-11-19 08:00AM  
Dec-10-19 08:00AM  
Dec-04-19 08:00AM  
07:06AM  
Dec-03-19 04:05PM  
03:29PM  
Nov-11-19 10:56AM  
Oct-30-19 08:49PM  
Jul-30-19 03:25PM  
Jul-28-19 02:08PM  
Jul-05-19 05:24PM  
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HO WILLIAMChief Medical OfficerJan 15Sale21.051,00021,05067,414Jan 15 08:52 PM
Brockstedt Dirk G.Chief Scientific OfficerJan 06Sale19.681,17923,20317,556Jan 06 08:48 PM
Brockstedt Dirk G.Chief Scientific OfficerJan 05Sale19.7682116,22518,735Jan 06 08:48 PM
HO WILLIAMChief Medical OfficerJan 04Sale19.751,00019,75068,414Jan 04 08:04 PM
Brockstedt Dirk G.Chief Scientific OfficerDec 30Option Exercise6.189,30057,47419,556Dec 31 06:09 PM
HO WILLIAMChief Medical OfficerDec 15Sale24.551,00024,55069,414Dec 15 09:01 PM
HO WILLIAMChief Medical OfficerDec 01Sale21.831,00021,83070,414Dec 01 08:37 PM
RIEFLIN WILLIAM JLDirectorNov 19Buy16.2210,000162,20018,000Nov 20 03:56 PM
Robbins WendyeDirectorNov 19Buy16.095008,045500Nov 23 02:01 PM
Robbins WendyeDirectorNov 19Buy16.085008,0405,100Nov 23 02:01 PM
Brockstedt Dirk G.Chief Scientific OfficerNov 16Option Exercise6.269,87761,82120,133Nov 18 02:15 PM
HO WILLIAMChief Medical OfficerNov 16Option Exercise6.258,35652,24072,414Nov 18 02:16 PM
HO WILLIAMChief Medical OfficerNov 16Sale20.251,00020,25071,414Nov 18 02:16 PM
Brockstedt Dirk G.Chief Scientific OfficerNov 16Sale17.019,877168,00810,256Nov 18 02:15 PM
Brockstedt Dirk G.Chief Scientific OfficerNov 02Sale28.061,91053,59510,256Nov 03 08:32 PM
Lam Karen CVP, Finance and ControllerNov 02Sale28.142,02256,89912,735Nov 03 08:29 PM
HO WILLIAMChief Medical OfficerNov 02Sale28.061,00028,06064,058Nov 03 08:26 PM
HO WILLIAMChief Medical OfficerOct 15Sale35.761,00035,76065,058Oct 16 12:30 PM
Wong Brian RussellPresident and CEOOct 12Sale40.0520,000801,040337,000Oct 13 07:43 PM
HO WILLIAMChief Medical OfficerOct 12Sale40.202,00080,40066,058Oct 13 07:40 PM
HO WILLIAMChief Medical OfficerOct 01Sale31.181,00031,18068,058Oct 02 02:37 PM
Robbins WendyeDirectorSep 28Buy28.7050014,3506,550Sep 29 08:58 PM
HO WILLIAMChief Medical OfficerSep 24Option Exercise6.182,20013,59669,058Sep 25 04:44 PM
Robbins WendyeDirectorSep 24Buy28.002005,6006,050Sep 24 06:02 PM
Wong Brian RussellPresident and CEOSep 23Buy30.062,00060,120357,000Sep 23 03:11 PM
Robbins WendyeDirectorSep 23Buy29.2040011,6805,850Sep 24 06:02 PM
COLUMN GROUP II, LP10% OwnerSep 22Sale30.85608,00018,756,8003,835,679Sep 23 04:52 PM
Svennilson PeterDirectorSep 22Sale30.85608,00018,756,8003,835,679Sep 22 07:51 PM
HO WILLIAMChief Medical OfficerSep 15Sale36.141,00036,14066,858Sep 15 07:22 PM
HO WILLIAMChief Medical OfficerSep 01Sale26.241,00026,24067,858Sep 02 07:53 PM
Brockstedt Dirk G.Chief Scientific OfficerAug 17Option Exercise6.189,87761,04020,133Aug 18 07:44 PM
HO WILLIAMChief Medical OfficerAug 17Sale24.761,00024,76068,858Aug 18 07:46 PM
Brockstedt Dirk G.Chief Scientific OfficerAug 17Sale23.939,877236,32810,256Aug 18 07:44 PM
Svennilson PeterDirectorAug 17Sale22.75538,65412,254,3794,443,679Aug 19 05:41 PM
COLUMN GROUP II, LP10% OwnerAug 17Sale22.75538,65412,254,3794,443,679Aug 19 05:39 PM
HO WILLIAMChief Medical OfficerAug 03Sale21.541,00021,54069,858Aug 03 07:42 PM
Robbins WendyeDirectorJul 24Buy22.4790020,2255,450Jul 27 06:38 PM
HO WILLIAMChief Medical OfficerJul 15Sale28.761,00028,76070,858Jul 16 08:13 PM
Robbins WendyeDirectorJul 01Buy26.401,00026,4004,550Jul 01 06:16 PM
HO WILLIAMChief Medical OfficerJul 01Sale28.611,00028,61071,858Jul 01 07:20 PM
Robbins WendyeDirectorJun 29Buy25.771,60041,2323,550Jul 01 06:16 PM
Giordano Michael FDirectorJun 25Option Exercise8.9219,013169,55410,069Jun 26 05:49 PM
Lam Karen CVP, Finance & ControllerJun 25Sale35.0087530,62512,735Jun 26 05:46 PM
Giordano Michael FDirectorJun 25Sale33.3719,013634,4640Jun 26 05:49 PM
HO WILLIAMChief Medical OfficerJun 15Sale20.951,00020,95072,858Jun 18 06:41 PM
HO WILLIAMChief Medical OfficerJun 01Sale18.501,00018,50073,858Jun 02 05:49 PM
HO WILLIAMChief Medical OfficerMay 22Sale18.027,500135,15074,858May 22 08:14 PM
Brockstedt Dirk G.Chief Scientific OfficerMay 15Option Exercise6.189,87761,04020,133May 18 05:11 PM
Brockstedt Dirk G.Chief Scientific OfficerMay 15Sale15.009,877148,15510,256May 18 05:11 PM
Lam Karen CVP, Finance & ControllerMay 12Option Exercise1.862,7775,16513,610May 13 05:15 PM
Lam Karen CVP, Finance & ControllerMay 07Sale15.401,83128,19710,833May 08 05:34 PM